JP2022518060A5 - - Google Patents

Info

Publication number
JP2022518060A5
JP2022518060A5 JP2021543372A JP2021543372A JP2022518060A5 JP 2022518060 A5 JP2022518060 A5 JP 2022518060A5 JP 2021543372 A JP2021543372 A JP 2021543372A JP 2021543372 A JP2021543372 A JP 2021543372A JP 2022518060 A5 JP2022518060 A5 JP 2022518060A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
antibody
individual
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021543372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022518060A (ja
JP7712206B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/015455 external-priority patent/WO2020160020A1/en
Publication of JP2022518060A publication Critical patent/JP2022518060A/ja
Publication of JP2022518060A5 publication Critical patent/JP2022518060A5/ja
Priority to JP2025115594A priority Critical patent/JP2025148430A/ja
Application granted granted Critical
Publication of JP7712206B2 publication Critical patent/JP7712206B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021543372A 2019-01-28 2020-01-28 多発性骨髄腫の処置方法 Active JP7712206B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025115594A JP2025148430A (ja) 2019-01-28 2025-07-09 多発性骨髄腫の処置方法

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201962797876P 2019-01-28 2019-01-28
US62/797,876 2019-01-28
US201962847826P 2019-05-14 2019-05-14
US62/847,826 2019-05-14
US201962861954P 2019-06-14 2019-06-14
US62/861,954 2019-06-14
US201962899094P 2019-09-11 2019-09-11
US62/899,094 2019-09-11
US201962931014P 2019-11-05 2019-11-05
US62/931,014 2019-11-05
EP19306554 2019-12-03
EP19306554.7 2019-12-03
US201962943716P 2019-12-04 2019-12-04
US62/943,716 2019-12-04
PCT/US2020/015455 WO2020160020A1 (en) 2019-01-28 2020-01-28 Methods of treating multiple myeloma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025115594A Division JP2025148430A (ja) 2019-01-28 2025-07-09 多発性骨髄腫の処置方法

Publications (3)

Publication Number Publication Date
JP2022518060A JP2022518060A (ja) 2022-03-11
JP2022518060A5 true JP2022518060A5 (cg-RX-API-DMAC10.html) 2023-02-22
JP7712206B2 JP7712206B2 (ja) 2025-07-23

Family

ID=69646031

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021543372A Active JP7712206B2 (ja) 2019-01-28 2020-01-28 多発性骨髄腫の処置方法
JP2025115594A Pending JP2025148430A (ja) 2019-01-28 2025-07-09 多発性骨髄腫の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025115594A Pending JP2025148430A (ja) 2019-01-28 2025-07-09 多発性骨髄腫の処置方法

Country Status (15)

Country Link
US (2) US11939390B2 (cg-RX-API-DMAC10.html)
EP (2) EP4588484A3 (cg-RX-API-DMAC10.html)
JP (2) JP7712206B2 (cg-RX-API-DMAC10.html)
KR (1) KR20210120048A (cg-RX-API-DMAC10.html)
CN (2) CN120754030A (cg-RX-API-DMAC10.html)
AU (1) AU2020215692A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021014699A2 (cg-RX-API-DMAC10.html)
CA (1) CA3127928A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021011034A2 (cg-RX-API-DMAC10.html)
IL (2) IL285110B2 (cg-RX-API-DMAC10.html)
MA (1) MA54860A (cg-RX-API-DMAC10.html)
MX (1) MX2021009079A (cg-RX-API-DMAC10.html)
SG (1) SG11202108029XA (cg-RX-API-DMAC10.html)
TW (2) TW202535952A (cg-RX-API-DMAC10.html)
WO (1) WO2020160020A1 (cg-RX-API-DMAC10.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913777XA (en) 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
EP3191524A4 (en) 2014-09-12 2018-05-30 The Regents of The University of California Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics
IL285110B2 (en) 2019-01-28 2025-11-01 Sanofi Sa Methods of treating multiple myeloma
CN120501855A (zh) * 2019-05-14 2025-08-19 赛诺菲-安万特美国有限责任公司 给予抗cd38抗体以治疗多发性骨髓瘤的方法
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
AU2020397170A1 (en) * 2019-12-05 2022-07-21 Sanofi-Aventis U.S. Llc Formulations of anti-CD38 antibodies for subcutaneous administration
JP2023534765A (ja) * 2020-08-07 2023-08-10 フォーティス セラピューティクス,インク. 免疫複合体を標的とするcd46およびその使用方法
IL302640A (en) * 2020-11-03 2023-07-01 Sanofi Aventis Us Llc Use of isatuximab for the treatment of multiple myeloma
CA3204579A1 (en) * 2021-01-07 2022-07-14 Bin Liu Combination therapy with for46 for cancer
CN114219787B (zh) * 2021-12-17 2024-08-06 三峡大学 一种初诊多发性骨髓瘤预后分期系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2551282A3 (en) * 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
KR20210073616A (ko) * 2012-08-09 2021-06-18 셀진 코포레이션 면역-관련 및 염증성 질환의 치료
US10617757B2 (en) * 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
US10533057B2 (en) * 2015-05-13 2020-01-14 Morphosys Ag Treatment for multiple myeloma (MM)
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
CN107708734B (zh) * 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
GB201521217D0 (en) * 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens
BR112019011138A2 (pt) * 2016-12-02 2019-10-01 Rubius Therapeutics, Inc. composições e métodos relacionados com sistemas celulares para penetração em tumores sólidos
IL271946B (en) * 2017-07-09 2022-09-01 Biosight Ltd Combination cancer therapy
IL285110B2 (en) 2019-01-28 2025-11-01 Sanofi Sa Methods of treating multiple myeloma

Similar Documents

Publication Publication Date Title
US20240417455A1 (en) Treatment for rheumatoid arthritis
JP2023517236A5 (cg-RX-API-DMAC10.html)
TWI890481B (zh) 雙特異性抗體
JP2021502961A5 (cg-RX-API-DMAC10.html)
JP2005533861A5 (cg-RX-API-DMAC10.html)
JP2020509031A5 (cg-RX-API-DMAC10.html)
US12527784B2 (en) Combined pharmaceutical composition for treating small cell lung cancer
JP2017507931A5 (cg-RX-API-DMAC10.html)
JP2022532356A5 (cg-RX-API-DMAC10.html)
JP2022512875A5 (cg-RX-API-DMAC10.html)
JP2019516767A (ja) 癌の治療のためのペンブロリズマブとアベマシクリブとの組合せ
US20250295765A1 (en) Drug combination for treating non-small cell lung cancer
JP2023515675A5 (cg-RX-API-DMAC10.html)
JP2023539625A5 (cg-RX-API-DMAC10.html)
JP2024528640A (ja) 癌処置の組合せ薬
TWI870592B (zh) 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
JP2022531205A5 (cg-RX-API-DMAC10.html)
JP2021523138A5 (cg-RX-API-DMAC10.html)
JP2025515076A5 (cg-RX-API-DMAC10.html)
JP2022514561A5 (cg-RX-API-DMAC10.html)
JP2023505219A5 (cg-RX-API-DMAC10.html)
JP2023506779A5 (cg-RX-API-DMAC10.html)
WO2025122791A1 (en) Use of anti-cd38 antibody in the treatment of new diagnosed multiple myeloma
JPH01316398A (ja) 新規ペプチド、その塩及びペプチド性抗アレルギー剤
JP2023504209A5 (cg-RX-API-DMAC10.html)